Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegvaliase - BioMarin Pharmaceutical

Drug Profile

Pegvaliase - BioMarin Pharmaceutical

Alternative Names: BMN-165; Palynziq; PEG-PAL; Pegvaliase-pqpz; PEGylated phenylalanine ammonia lyase; Pegylated recombinant Anabaena variabilis phenylalanine ammonia lyase; PEGylated recombinant phenylalanine ammonia lyase; Phenylase; rAvPAL-PEG

Latest Information Update: 23 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IBEX Technologies
  • Developer BioMarin Pharmaceutical
  • Class Ammonia lyases; Enzymes; Recombinant proteins
  • Mechanism of Action Phenylalanine ammonia lyase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Phenylketonuria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Phenylketonuria

Most Recent Events

  • 01 Aug 2019 BioMarin Pharmaceutical anticipates to launch pegvaliase for Phenylketonuria in Europe in 3Q of 2019
  • 07 May 2019 Updated efficacy data from the phase II PAL-003 in Phenylketonuria released by BioMarin Pharmaceutical
  • 07 May 2019 Updated efficacy data from the phase III Prism302 in Phenylketonuria released by BioMarin Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top